id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-N-5830-0001,FDA,FDA-2024-N-5830,Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal,Notice,Notice of Renewal,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2024-12-31T14:00:03Z,2024-31363,0,0,0900006486896cc5